Changes in Regional Ventilation-Perfusion Match Following Percutaneous Transluminal Angioplasty for Arteriovenous Graft Thrombosis
Recruiting
Observational Study
Arteriovenous Graft Thrombosis
End Stage Renal Disease on Dialysis
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 20 (estimated)
- Sponsor
- First Affiliated Hospital of Wannan Medical College · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Patients with end-stage renal disease (ESRD) often require arteriovenous grafts (AVG) for hemodialysis. AVG thrombosis is a common complication, usually managed by percutaneous transluminal angioplasty (PTA) to restore blood flow. PTA achieves patency by balloon-mediated compression and fragmentation of thrombus. Small thrombus fragments may enter the venous circulation and cause transient pulmona…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria
1. Age ≥ 18 years.
2. Diagnosis of end-stage renal disease receiving maintenance hemodialysis.
3. Documented AVG thrombosis requiring PTA.
4. Able to cooperate and tolerate EIT monitoring.
5. Provided written informed consent.
Exclusion Criteria
1. Severe respiratory failure in…
Contacts